SCHEMBL25311112

SCHEMBL25311112

NC1CCN(C(=O)c2cccc(-c3cn4ccccc4n3)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.55
ALDH1A1 P00352 10/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
HPGD P15428 4/20 0.55
RAB9A P51151 4/20 0.54
LMNA P02545 4/20 0.54
POLB P06746 3/20 0.54
GFER P55789 2/20 0.54
KMT2A Q03164 3/20 0.50
MAPT P10636 2/20 0.50
GAA P10253 3/20 0.49
CLK1 P49759 1/20 0.49
DYRK1A Q13627 1/20 0.49
NPC1 O15118 1/20 0.48
TP53 P04637 1/20 0.48
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
MEN1 O00255 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25311377 0.90 KDM4E (0.62) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL19322175 0.88 KDM4E (0.60) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL28709673 0.87 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL25878977 0.86 KDM4E (0.55) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL29484624 0.85 RAB9A (0.56) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL25311960 0.85 KDM4E (0.56) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL25311588 0.85 RAB9A (0.56) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL25312109 0.84 KDM4E (0.56) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL25310936 0.84 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL30471101 0.82 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2024-03-28 US disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
WO-2022057932-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-03-24 WO disclosed
WO-2022057928-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-03-24 WO disclosed
CN-114195780-A Carbonyl heterocyclic compound and application thereof 上海医药集团股份有限公司 2022-03-18 CN disclosed
CN-114195806-A Carbonyl heterocyclic compound and application thereof 上海医药集团股份有限公司 2022-03-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LANCL2, CBS, LCP2 KDM4E 2757/4885ALDH1A1 3956/4885SMN1; SMN2 3536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.